About this trial
The goal of this clinical trial is to learn if a chatbot powered by artificial intelligence works to improve HPV vaccination among females aged 15 to 26 in China. A randomized controlled trial and implementation science study will be conducted targeting females as participants. The main questions it aims to answer are:
1. Does the vaccine chatbot influence women's confidence, literacy, hesitancy, and uptake of the HPV vaccine. 2. What are the public acceptance of chatbot and the facilitators and barriers to its implementation in a real-world setting.
Researchers will compare a group of women who use the chatbot with a group who do not use it to see if the chatbot is effective at helping women feel confident and willing to get vaccinated against HPV.
Participants will:
1. Be recruited and randomly allocated into one of two groups. One group will be invited to use the HPV vaccine chatbot and the other group will not get access to the vaccine chatbot until the end of the trial. 2. Complete a questionnaire survey on their confidence, literacy, and hesitancy on the HPV vaccine. 3. Have their vaccination status checked at the end of trial.
Eligibility criteria
Qualifiers
Female, aged 15 to 26 years, inclusive.
Not previously vaccinated against HPV.
Reports no contraindications to HPV vaccination.
Has no mental, visual, or reading impairments that would preclude cooperation with study activities.
Disqualifiers
Male.
Age under 15 or over 26 years.
Has a history of prior HPV vaccination.
Has a known contraindication to HPV vaccination.
Trial design
Treatments tested in this trial
- LLM-Powered HPV Vaccine Chatbot
Treatment groups
Locations
Sponsors and collaborators
Fudan University
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator